Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Current Deferred Revenue (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Current Deferred Revenue for 12 consecutive years, with $927000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue changed 0.0% to $927000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $927000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $927000.0 for FY2025, 0.0% changed from the prior year.
  • Current Deferred Revenue for Q4 2025 was $927000.0 at Plus Therapeutics, down from $2.0 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $2.3 million in Q2 2024, with the low at $247000.0 in Q1 2024.
  • Average Current Deferred Revenue over 3 years is $1.2 million, with a median of $927000.0 recorded in 2024.
  • The sharpest move saw Current Deferred Revenue crashed 78.28% in 2024, then surged 425.1% in 2025.
  • Over 3 years, Current Deferred Revenue stood at $1.1 million in 2023, then decreased by 18.47% to $927000.0 in 2024, then changed by 0.0% to $927000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $927000.0, $2.0 million, and $927000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.